The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Putilina M.V.

Pirogov Russian National Research Medical University

Mutovina Z.Yu.

Moscow City Hospital No. 52;
Central State Medical Academy

Kurushina O.V.

Volgograd State Medical University

Khalilova D.M.

Azerbaijan State Medical University

Saverskaya E.N.

Medical Continuing Education Institute of the Moscow State Food Production University

Stepanova S.B.

South Ural State Medical University

Khoreva M.A.

Altai State Medical University

Starikov A.S.

Pitirim Sorokin Syktyvkar State University

Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX

Authors:

Putilina M.V., Mutovina Z.Yu., Kurushina O.V., Khalilova D.M., Saverskaya E.N., Stepanova S.B., Khoreva M.A., Starikov A.S.

More about the authors

Read: 28425 times


To cite this article:

Putilina MV, Mutovina ZYu, Kurushina OV, et al. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1):84‑90. (In Russ.)
https://doi.org/10.17116/jnevro202212201184

References:

  1. Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long-term effects of COVID-19: a summary of the recommendations NICE and RCGP. BMJ. 2021;372:136-140.  https://doi.org/10.1136/bmj.n13
  2. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232.  https://doi.org/10.1016/S0140-6736(20)32656-8
  3. Chopra B, Flanders SA, O’Malley M. Sixty-day results among patients hospitalized with COVID-19. Ann Intern Med. 2021;174:576-578.  https://doi.org/10.7326/M20-5661
  4. Crook H, Raza S, Nowell J, et al. Long covid — mechanisms, risk factors, and management. BMJ. 2021;374:n1648. https://doi.org/10.1136/bmj.n1648
  5. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.  https://doi.org/10.1038/s41591-021-01283-z
  6. Clinical guidelines of the Ministry of Health of the Russian Federation for the prevention, diagnosis and treatment of a new coronavirus infectionCOVID-19 version 13: 238. (In Russ.). https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf
  7. Putilina MV, Teplova NV, Bairova KI, et al. The result of prospective randomized study CITADEL — the efficacy and safety of drug Cytoflavin in postcovid rehabilitation. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(10):39-45. (In Russ.). https://doi.org/10.17116/jnevro202112110139
  8. https://doi.org/10.17116/jnevro2021121081119  https://doi.org/10.17116/jnevro2021121081119
  9. Soudy R, Kimura R, Patel A. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Sci Rep. 2019;9:10942. https://doi.org/10.1038/s41598-019-47255-9
  10. Putilina MV, Grishin DV. SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(8):58-64. (In Russ.). https://doi.org/10.17116/jnevro202012008258
  11. Zhou X, Smith QR, Liu, X. Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood-brain barrier and combating diseases of the central nervous system. WIRES Nanomed Nanobiotechnol. 2021;6:e1695. https://doi.org/10.1002/wnan.1695
  12. Lee J, Kim C. Peptide Materials for Smart Therapeutic Applications. Macromol Res. 2021;29:2-14.  https://doi.org/10.1007/s13233-021-9011-x
  13. Lee J, Zheng M, Shimoni O, et al. Development of New Therapeutics Aimed at blood-brain barrier: from barrier to carrier. Adv Sci. 2021;8:21-28.  https://doi.org/10.1002/advs.202101090
  14. Yakovlev AA, Gulyaeva NV. Molecular partners of cortexin in the brain. Neurochemistry. 2017;33:1:91-96. (In Russ.). https://doi.org/10.1134/S1819712416040164
  15. Nesterenko AN, Onufriev MV, Gulyaeva NV, et al. Effect of the drug Cortexin on free radical oxidation and inflammatory processes in rats with normal and accelerated aging. Neurochemistry. 2018;2(35):187-198. (In Russ.). https://doi.org/10.7868/S1027813318020127.
  16. Tsygan VN. Chronic fatigue syndrome and its correction with Cortexin. Russian Medical Journal. 2010;16:1004-1008. (In Russ.).
  17. Ludewig P, Winneberger J, Magnus T. The cerebral endothelial cell as a key regulator of inflammatory processes in sterile inflammation. J Neuroimmunol. 2019;326:38-44.  https://doi.org/10.1016/j.jneuroim.2018.10.012
  18. Kurkin D, Bakulin D, Morkovin E. et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS ONE. 2021;16(7):E0254493. https://doi.org/10.1371/journal.pone.0254493
  19. Putilina MV, Vechorko VI, Grishin DV, Sidelnikova LV. Acute cerebrovascular accidents associated with SARS-CoV-2 coronavirus infection (COVID-19) Journal of Neurology and Psychiatry. S.S. Korsakov. 2020;120(12):109-118. (In Russ.). https://doi.org/10.17116/jnevro2020120121109
  20. Putilina MV, Soldatov MA. Cerebral strokes in old age. Features of the clinical picture, course, treatment. Doctor. 2006;5:29-34. (In Russ.).
  21. Serebrovska ZO, Chong EY, Serebrovska TV. Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to therapeutic targets. Acta Pharmacol Sin. 2020;41:1539-1546. https://doi.org/10.1038/s41401-020-00554-8
  22. Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021:S0188-4409(21)00081-3.  https://doi.org/10.1016/j.arcmed.2021.03.010.
  23. Putilina MV, Baranova OA. Results of the multicenter clinical and epidemiological observational program «GLOBUS» (determination of the prevalence of dizziness and assessment of therapy regimens at the outpatient level). Journal of Neurology and Psychiatry. S.S. Korsakov. 2014;114(5):33-38. (In Russ.).
  24. Zhang J, Zhou Y. 14-3-3 Proteins in Glutamatergic Synapses. Hindawi Neural Plasticity. 2018;23:23-29.  https://doi.org/10.1155/2018/8407609
  25. Putilina MV, Teplova NV, Poryadin GV. Prospects for pharmacological adaptation of neurovascular unit in conditions of neurotropic viral infection. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5):89-95. (In Russ.). https://doi.org/10.17116/jnevro2021121051144
  26. Fedin AI, Bel’skaia GN, Kurushina OV, et al. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(9):35-42. (In Russ.). https://doi.org/10.17116/jnevro201811809135

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.